Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 111 entries
Sorted by: Best Match Show Resources per page
The role of teachers' motivation and mindsets in predicting a (de) motivating teaching style in higher education: A circumplex approach

Growth Mindset STEM Intervention

Beyers W, Vermote B.
GSID: 2w9g5mehEZIJ
B Vermote, N Aelterman, W Beyers, L Aper… - Motivation and …, 2020 - Springer

… Autonomous motivation and a growth mindset related … Following these item stems, participants rated items tapping into … in the intervention, participants reported having more growth …

Cite
Vermote, B., Aelterman, N., Beyers, W., Aper, L., Buysschaert, F., & Vansteenkiste, M. (2020). The role of teachers’ motivation and mindsets in predicting a (de) motivating teaching style in higher education: A circumplex approach. Motivation and emotion, 44, 270-294.
Vermote, Branko, et al. "The role of teachers’ motivation and mindsets in predicting a (de) motivating teaching style in higher education: A circumplex approach." Motivation and emotion 44 (2020): 270-294.
Copy Download .nbib Format: MLA
The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for ovarian cancer.

Journal for immunotherapy of cancer

Baert T, Verschuere T, Van Hoylandt A, Gijsbers R, Vergote I, Coosemans A.
PMID: 26676113
J Immunother Cancer. 2015 Dec 15;3:57. doi: 10.1186/s40425-015-0102-0. eCollection 2015.

Reliable mouse models are key in the discovery and development of novel anticancer treatments. Non-invasive monitoring techniques such as bioluminescence imaging (BLI) are useful tools to determine tumor engraftment and evaluate tumor growth. However, the development of ascites in...

Cite
Baert T, Verschuere T, Van Hoylandt A, et al. The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for ovarian cancer. J Immunother Cancer. 2015;3:57doi: 10.1186/s40425-015-0102-0.
Baert, T., Verschuere, T., Van Hoylandt, A., Gijsbers, R., Vergote, I., & Coosemans, A. (2015). The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for ovarian cancer. Journal for immunotherapy of cancer, 357. https://doi.org/10.1186/s40425-015-0102-0
Baert, Thaïs, et al. "The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for ovarian cancer." Journal for immunotherapy of cancer vol. 3 (2015): 57. doi: https://doi.org/10.1186/s40425-015-0102-0
Baert T, Verschuere T, Van Hoylandt A, Gijsbers R, Vergote I, Coosemans A. The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for ovarian cancer. J Immunother Cancer. 2015 Dec 15;3:57. doi: 10.1186/s40425-015-0102-0. eCollection 2015. PMID: 26676113; PMCID: PMC4678634.
Copy Download .nbib Format: NLM
Complete Genome Sequence of Nova Virus, a Hantavirus Circulating in the European Mole in Belgium.

Genome announcements

Laenen L, Vergote V, Nauwelaers I, Verbeeck I, Kafetzopoulou LE, Van Ranst M, Maes P.
PMID: 26251483
Genome Announc. 2015 Aug 06;3(4). doi: 10.1128/genomeA.00770-15.

The complete genome sequence of Nova virus, a divergent hantavirus, originating from the kidney tissue of a European mole (Talpa europaea) from Belgium was determined. The 3 genomic segments have a total length of 11,979 nucleotides, and nucleotide identities...

Cite
Laenen L, Vergote V, Nauwelaers I, et al. Complete Genome Sequence of Nova Virus, a Hantavirus Circulating in the European Mole in Belgium. Genome Announc. 2015;3(4)doi: 10.1128/genomeA.00770-15.
Laenen, L., Vergote, V., Nauwelaers, I., Verbeeck, I., Kafetzopoulou, L. E., Van Ranst, M., & Maes, P. (2015). Complete Genome Sequence of Nova Virus, a Hantavirus Circulating in the European Mole in Belgium. Genome announcements, 3(4), . https://doi.org/10.1128/genomeA.00770-15
Laenen, Lies, et al. "Complete Genome Sequence of Nova Virus, a Hantavirus Circulating in the European Mole in Belgium." Genome announcements vol. 3,4 (2015). doi: https://doi.org/10.1128/genomeA.00770-15
Laenen L, Vergote V, Nauwelaers I, Verbeeck I, Kafetzopoulou LE, Van Ranst M, Maes P. Complete Genome Sequence of Nova Virus, a Hantavirus Circulating in the European Mole in Belgium. Genome Announc. 2015 Aug 06;3(4). doi: 10.1128/genomeA.00770-15. PMID: 26251483; PMCID: PMC4541267.
Copy Download .nbib Format: NLM
Alzheimer's Genetic Risk Intensifies Neurocognitive Slowing Associated with Diabetes in Non-Demented Older Adults.

Alzheimer's & dementia (Amsterdam, Netherlands)

McFall GP, Wiebe SA, Vergote D, Anstey KJ, Dixon RA.
PMID: 26665159
Alzheimers Dement (Amst). 2015 Dec;1(4):395-402. doi: 10.1016/j.dadm.2015.08.002.

INTRODUCTION: We examine interactive and intensification effects of type 2 diabetes (T2D) with METHODS: In an accelerated longitudinal design, we used latent growth modeling to test moderators of level and change in a neurocognitive speed latent variable for 628...

Cite
McFall GP, Wiebe SA, Vergote D, et al. Alzheimer's Genetic Risk Intensifies Neurocognitive Slowing Associated with Diabetes in Non-Demented Older Adults. Alzheimers Dement (Amst). 2015;1(4):395-402doi: 10.1016/j.dadm.2015.08.002.
McFall, G. P., Wiebe, S. A., Vergote, D., Anstey, K. J., & Dixon, R. A. (2015). Alzheimer's Genetic Risk Intensifies Neurocognitive Slowing Associated with Diabetes in Non-Demented Older Adults. Alzheimer's & dementia (Amsterdam, Netherlands), 1(4), 395-402. https://doi.org/10.1016/j.dadm.2015.08.002
McFall, G Peggy, et al. "Alzheimer's Genetic Risk Intensifies Neurocognitive Slowing Associated with Diabetes in Non-Demented Older Adults." Alzheimer's & dementia (Amsterdam, Netherlands) vol. 1,4 (2015): 395-402. doi: https://doi.org/10.1016/j.dadm.2015.08.002
McFall GP, Wiebe SA, Vergote D, Anstey KJ, Dixon RA. Alzheimer's Genetic Risk Intensifies Neurocognitive Slowing Associated with Diabetes in Non-Demented Older Adults. Alzheimers Dement (Amst). 2015 Dec;1(4):395-402. doi: 10.1016/j.dadm.2015.08.002. PMID: 26665159; PMCID: PMC4671298.
Copy Download .nbib Format: NLM
Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Makar AP, Kaern J, Kristensen GB, Vergote I, Børmer OP, Tropé CG.
PMID: 11578361
Int J Gynecol Cancer. 1993 Sep;3(5):299-303. doi: 10.1046/j.1525-1438.1993.03050299.x.

Serum CA 125 was evaluated as a tumor marker in 85 patients with borderline ovarian tumors. Serum CA 125 levels were elevated preoperatively in 18 of 20 (90%) samples (median 66, range 5-272 U ml-1). Preoperative serum CA 125...

Cite
Makar AP, Kaern J, Kristensen GB, et al. Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary. Int J Gynecol Cancer. 1993;3(5):299-303doi: 10.1046/j.1525-1438.1993.03050299.x.
Makar, A. P., Kaern, J., Kristensen, G. B., Vergote, I., Børmer, O. P., & Tropé, C. G. (1993). Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 3(5), 299-303. https://doi.org/10.1046/j.1525-1438.1993.03050299.x
Makar, A.Ph., et al. "Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society vol. 3,5 (1993): 299-303. doi: https://doi.org/10.1046/j.1525-1438.1993.03050299.x
Makar AP, Kaern J, Kristensen GB, Vergote I, Børmer OP, Tropé CG. Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary. Int J Gynecol Cancer. 1993 Sep;3(5):299-303. doi: 10.1046/j.1525-1438.1993.03050299.x. PMID: 11578361.
Copy Download .nbib Format: NLM
High-grade endometrial stromal sarcoma presenting in a 28-year-old woman during pregnancy: a case report.

Journal of medical case reports

Amant F, Van Calsteren K, Debiec-Rychter M, Heyns L, De Beeck KO, Sagaert X, Bollen B, Vergote I.
PMID: 20684773
J Med Case Rep. 2010 Aug 04;4:243. doi: 10.1186/1752-1947-4-243.

INTRODUCTION: To the best of our knowledge, soft tissue sarcomas have not prevously been reported as a complication during pregnancy.CASE PRESENTATION: A 28-year-old Caucasian woman was diagnosed with a transperitoneal sarcoma during pregnancy. Morphological, immunohistochemical, chromosomal and mutational analyses...

Cite
Amant F, Van Calsteren K, Debiec-Rychter M, et al. High-grade endometrial stromal sarcoma presenting in a 28-year-old woman during pregnancy: a case report. J Med Case Rep. 2010;4:243doi: 10.1186/1752-1947-4-243.
Amant, F., Van Calsteren, K., Debiec-Rychter, M., Heyns, L., De Beeck, K. O., Sagaert, X., Bollen, B., & Vergote, I. (2010). High-grade endometrial stromal sarcoma presenting in a 28-year-old woman during pregnancy: a case report. Journal of medical case reports, 4243. https://doi.org/10.1186/1752-1947-4-243
Amant, Frédéric, et al. "High-grade endometrial stromal sarcoma presenting in a 28-year-old woman during pregnancy: a case report." Journal of medical case reports vol. 4 (2010): 243. doi: https://doi.org/10.1186/1752-1947-4-243
Amant F, Van Calsteren K, Debiec-Rychter M, Heyns L, De Beeck KO, Sagaert X, Bollen B, Vergote I. High-grade endometrial stromal sarcoma presenting in a 28-year-old woman during pregnancy: a case report. J Med Case Rep. 2010 Aug 04;4:243. doi: 10.1186/1752-1947-4-243. PMID: 20684773; PMCID: PMC2925352.
Copy Download .nbib Format: NLM
Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium.

Oncotarget

Obermayr E, Bednarz-Knoll N, Orsetti B, Weier HU, Lambrechts S, Castillo-Tong DC, Reinthaller A, Braicu EI, Mahner S, Sehouli J, Vergote I, Theillet C, Zeillinger R, Brandt B.
PMID: 29290959
Oncotarget. 2017 Nov 16;8(63):106415-106428. doi: 10.18632/oncotarget.22468. eCollection 2017 Dec 05.

PURPOSE: In 75% of ovarian cancer patients the tumor mass is completely eradicated by established surgical and cytotoxic treatment; however, the majority of the tumors recur within 24 months. Here we investigated the role of circulating tumor cells (CTCs)...

Cite
Obermayr E, Bednarz-Knoll N, Orsetti B, et al. Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. Oncotarget. 2017;8(63):106415-106428doi: 10.18632/oncotarget.22468.
Obermayr, E., Bednarz-Knoll, N., Orsetti, B., Weier, H. U., Lambrechts, S., Castillo-Tong, D. C., Reinthaller, A., Braicu, E. I., Mahner, S., Sehouli, J., Vergote, I., Theillet, C., Zeillinger, R., & Brandt, B. (2017). Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. Oncotarget, 8(63), 106415-106428. https://doi.org/10.18632/oncotarget.22468
Obermayr, Eva, et al. "Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium." Oncotarget vol. 8,63 (2017): 106415-106428. doi: https://doi.org/10.18632/oncotarget.22468
Obermayr E, Bednarz-Knoll N, Orsetti B, Weier HU, Lambrechts S, Castillo-Tong DC, Reinthaller A, Braicu EI, Mahner S, Sehouli J, Vergote I, Theillet C, Zeillinger R, Brandt B. Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. Oncotarget. 2017 Nov 16;8(63):106415-106428. doi: 10.18632/oncotarget.22468. eCollection 2017 Dec 05. PMID: 29290959; PMCID: PMC5739744.
Copy Download .nbib Format: NLM
Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer.

Oncology letters

Mungenast F, Aust S, Vergote I, Vanderstichele A, Sehouli J, Braicu E, Mahner S, Castillo-Tong DC, Zeillinger R, Thalhammer T.
PMID: 28588698
Oncol Lett. 2017 Jun;13(6):4047-4054. doi: 10.3892/ol.2017.5969. Epub 2017 Apr 03.

17β-estradiol (E2) can contribute to the progression of epithelial ovarian cancer (EOC). Although the majority of patients with EOC are postmenopausal woman, when de novo estrogen production in the ovary has ceased, ovarian cancer cells remain exposed to estrogens...

Cite
Mungenast F, Aust S, Vergote I, et al. Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer. Oncol Lett. 2017;13(6):4047-4054doi: 10.3892/ol.2017.5969.
Mungenast, F., Aust, S., Vergote, I., Vanderstichele, A., Sehouli, J., Braicu, E., Mahner, S., Castillo-Tong, D. C., Zeillinger, R., & Thalhammer, T. (2017). Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer. Oncology letters, 13(6), 4047-4054. https://doi.org/10.3892/ol.2017.5969
Mungenast, Felicitas, et al. "Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer." Oncology letters vol. 13,6 (2017): 4047-4054. doi: https://doi.org/10.3892/ol.2017.5969
Mungenast F, Aust S, Vergote I, Vanderstichele A, Sehouli J, Braicu E, Mahner S, Castillo-Tong DC, Zeillinger R, Thalhammer T. Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer. Oncol Lett. 2017 Jun;13(6):4047-4054. doi: 10.3892/ol.2017.5969. Epub 2017 Apr 03. PMID: 28588698; PMCID: PMC5452883.
Copy Download .nbib Format: NLM
Identifying the patterns and drivers of .

Virus evolution

Laenen L, Vergote V, Vanmechelen B, Tersago K, Baele G, Lemey P, Leirs H, Dellicour S, Vrancken B, Maes P.
PMID: 31024739
Virus Evol. 2019 Apr 22;5(1):vez009. doi: 10.1093/ve/vez009. eCollection 2019 Jan.

Hantaviruses are zoonotic hemorrhagic fever viruses for which prevention of human spillover remains the first priority in disease management. Tailored intervention measures require an understanding of the drivers of enzootic dynamics, commonly inferred from distorted human incidence data. Here,...

Cite
Laenen L, Vergote V, Vanmechelen B, et al. Identifying the patterns and drivers of . Virus Evol. 2019;5(1):vez009doi: 10.1093/ve/vez009.
Laenen, L., Vergote, V., Vanmechelen, B., Tersago, K., Baele, G., Lemey, P., Leirs, H., Dellicour, S., Vrancken, B., & Maes, P. (2019). Identifying the patterns and drivers of . Virus evolution, 5(1), vez009. https://doi.org/10.1093/ve/vez009
Laenen, Lies, et al. "Identifying the patterns and drivers of ." Virus evolution vol. 5,1 (2019): vez009. doi: https://doi.org/10.1093/ve/vez009
Laenen L, Vergote V, Vanmechelen B, Tersago K, Baele G, Lemey P, Leirs H, Dellicour S, Vrancken B, Maes P. Identifying the patterns and drivers of . Virus Evol. 2019 Apr 22;5(1):vez009. doi: 10.1093/ve/vez009. eCollection 2019 Jan. PMID: 31024739; PMCID: PMC6476162.
Copy Download .nbib Format: NLM
Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium.

Frontiers in oncology

Ray-Coquard I, Braicu I, Berger R, Mahner S, Sehouli J, Pujade-Lauraine E, Cassier PA, Moll UM, Ulmer H, Leunen K, Zeimet AG, Marth C, Vergote I, Concin N.
PMID: 31552170
Front Oncol. 2019 Sep 10;9:832. doi: 10.3389/fonc.2019.00832. eCollection 2019.

No abstract available.

Cite
Ray-Coquard I, Braicu I, Berger R, et al. Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium. Front Oncol. 2019;9:832doi: 10.3389/fonc.2019.00832.
Ray-Coquard, I., Braicu, I., Berger, R., Mahner, S., Sehouli, J., Pujade-Lauraine, E., Cassier, P. A., Moll, U. M., Ulmer, H., Leunen, K., Zeimet, A. G., Marth, C., Vergote, I., & Concin, N. (2019). Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium. Frontiers in oncology, 9832. https://doi.org/10.3389/fonc.2019.00832
Ray-Coquard, Isabelle, et al. "Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium." Frontiers in oncology vol. 9 (2019): 832. doi: https://doi.org/10.3389/fonc.2019.00832
Ray-Coquard I, Braicu I, Berger R, Mahner S, Sehouli J, Pujade-Lauraine E, Cassier PA, Moll UM, Ulmer H, Leunen K, Zeimet AG, Marth C, Vergote I, Concin N. Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium. Front Oncol. 2019 Sep 10;9:832. doi: 10.3389/fonc.2019.00832. eCollection 2019. PMID: 31552170; PMCID: PMC6746955.
Copy Download .nbib Format: NLM
Quality of Life Considerations in Gynecologic Cancer.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

Penson RT, Wenzel LB, Vergote I, Cella D.
PMID: 29644666
Int J Gynaecol Obstet. 2006 Nov;95:S247-S257. doi: 10.1016/S0020-7292(06)60040-4.

Quality of life (QOL) is a fundamental consideration for patients with life threatening diseases. Major evolving paradigms are discussed: improved QOL with laparoscopic surgery, the impact on QOL of intraperitoneal chemotherapy for optimally cytoreduced ovarian cancer, combination therapy, sexuality,...

Cite
Penson RT, Wenzel LB, Vergote I, et al. Quality of Life Considerations in Gynecologic Cancer. Int J Gynaecol Obstet. 2006;95:S247-S257doi: 10.1016/S0020-7292(06)60040-4.
Penson, R. T., Wenzel, L. B., Vergote, I., & Cella, D. (2006). Quality of Life Considerations in Gynecologic Cancer. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 95S247-S257. https://doi.org/10.1016/S0020-7292(06)60040-4
Penson, Richard T, et al. "Quality of Life Considerations in Gynecologic Cancer." International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics vol. 95 (2006): S247-S257. doi: https://doi.org/10.1016/S0020-7292(06)60040-4
Penson RT, Wenzel LB, Vergote I, Cella D. Quality of Life Considerations in Gynecologic Cancer. Int J Gynaecol Obstet. 2006 Nov;95:S247-S257. doi: 10.1016/S0020-7292(06)60040-4. PMID: 29644666.
Copy Download .nbib Format: NLM
Safety and dose modification for patients receiving niraparib.

Annals of oncology : official journal of the European Society for Medical Oncology

Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, Lesoin A, Colombo N, Vergote I, Rosengarten O, Ledermann J, Pineda M, Ellard S, Sehouli J, Gonzalez-Martin A, Berton-Rigaud D, Madry R, Reinthaller A, Hazard S, Guo W, Mirza MR.
PMID: 30107447
Ann Oncol. 2019 May 01;30(5):859. doi: 10.1093/annonc/mdy255.

No abstract available.

Cite
Berek JS, Matulonis UA, Peen U, et al. Safety and dose modification for patients receiving niraparib. Ann Oncol. 2019;30(5):859doi: 10.1093/annonc/mdy255.
Berek, J. S., Matulonis, U. A., Peen, U., Ghatage, P., Mahner, S., Redondo, A., Lesoin, A., Colombo, N., Vergote, I., Rosengarten, O., Ledermann, J., Pineda, M., Ellard, S., Sehouli, J., Gonzalez-Martin, A., Berton-Rigaud, D., Madry, R., Reinthaller, A., Hazard, S., Guo, W., & Mirza, M. R. (2019). Safety and dose modification for patients receiving niraparib. Annals of oncology : official journal of the European Society for Medical Oncology, 30(5), 859. https://doi.org/10.1093/annonc/mdy255
Berek, J S, et al. "Safety and dose modification for patients receiving niraparib." Annals of oncology : official journal of the European Society for Medical Oncology vol. 30,5 (2019): 859. doi: https://doi.org/10.1093/annonc/mdy255
Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, Lesoin A, Colombo N, Vergote I, Rosengarten O, Ledermann J, Pineda M, Ellard S, Sehouli J, Gonzalez-Martin A, Berton-Rigaud D, Madry R, Reinthaller A, Hazard S, Guo W, Mirza MR. Safety and dose modification for patients receiving niraparib. Ann Oncol. 2019 May 01;30(5):859. doi: 10.1093/annonc/mdy255. PMID: 30107447.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 111 entries